Collectively, these results demonstrate that the effect of tocilizumab in the cancer stem cell fraction correlates with the increased expression of its target receptor (IL-6R) in mucoepidermoid carcinoma stem cells. The gene discussed is IL6R; the disease is mucoepidermoid carcinoma.